How much funding has Allermi raised?

Allermi has raised $4.8M in total funding, most recently a seed round.

Who are Allermi's investors?

Allermi's investors include Nelstone Ventures, Lucas Venture Group.

Where is Allermi headquartered?

Allermi is headquartered in San Francisco, California, United States.

What industry is Allermi in?

Allermi operates in Healthcare, Digital Health.

Allermi

Personalized allergy care, delivered.

San Francisco, United States · Founded 2020 · $4.8M raised

Healthcare

Digital Health

Headquarters: San Francisco, California
Employees: 11–50
Founded: 2020
Business Model: B2C

Website: allermi.com
Total Funding: $4.8M
Last Round: $3.5M SeedMar 2023
Rounds: 2

About

Allermi is a telehealth company offering personalized prescription allergy nasal sprays compounded by pharmacists based on each patient's specific allergy profile. Founded by Stanford-trained allergists, Allermi replaces generic OTC allergy medications with evidence-based, custom-formulated sprays delivered directly to patients. The platform combines an online allergy assessment, physician review, and subscription-based delivery of custom treatments.

Summary

Allermi is a Healthcare company based in San Francisco, United States, founded in 2020. It has raised $4.8M in total across 2 rounds, most recently a $3.5M Seed round in Mar 2023. Investors include Nelstone Ventures and Lucas Venture Group.

LinkedIn X (Twitter)